{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:02:44Z","timestamp":1788303764459,"version":"build-2803163510"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations of the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). In 1949, it's been identified as a monogenic disease and was thought to primarily affect individuals of Northern European descent. It was the most prevalent autosomal recessive disease that shortens life. With the availability of multiple testing methodologies nowadays, there is a chance to create novel and enhanced treatment options. Even in the absence of a high sweat chloride test (SCT) result, the discovery of two causal mutations is diagnostic for cystic fibrosis (CF). For a CF diagnosis, however, at least two positive E sweat chloride tests are still required. In order to achieve early and active intervention to manage cystic fibrosis (CF) and its comorbidities, treatment regimens for pediatric patients should be evaluated, improved, and closely monitored. New developments in the treatment of cystic fibrosis (CF) have led to the development of medications derived from molecules that target the pathogenetic pathway of the illness. These options are very efficient and allow pediatric patients to receive individualized care. However, in order to better direct patient care and enhance patient outcomes, it is crucial to research uncommon CF mutations, which can provide crucial information about the prognosis of the disease and the relationships between genotype and phenotype. To ensure the success of creating novel, safer, and more efficient treatment approaches, a deeper understanding of the pathogeny of the illness is required. In the age of customized medicine, genetic research will be essential to improving patient care and quality of life for those with uncommon mutations.<\/jats:p>","DOI":"10.3389\/fped.2024.1393193","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:02:59Z","timestamp":1715317379000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Cystic fibrosis management in pediatric population\u2014from clinical features to personalized therapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Alice Nicoleta","family":"Azoicai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ancuta","family":"Lupu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Mihaela","family":"Trandafir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica Mihaela","family":"Alexoae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirabela","family":"Alecsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliana Magdalena","family":"Starcea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Cuciureanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Knieling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia Lidia","family":"Salaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Hanganu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Mocanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasile Valeriu","family":"Lupu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Ioniuc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1002\/ppul.25733","article-title":"Increasing life expectancy in cystic fibrosis: advances and challenges","volume":"57","author":"McBennett","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1007\/s00431-021-04168-y","article-title":"A new era for people with cystic fibrosis","volume":"180","author":"Bierlaagh","year":"2021","journal-title":"Eur J Pediatr"},{"key":"B4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jhep.2021.09.042","article-title":"Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies","volume":"76","author":"Dana","year":"2022","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1001\/jama.289.22.2923","article-title":"Cystic fibrosis gene testing a challenge","volume":"289","author":"Vastag","year":"2003","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.arbres.2013.07.013","article-title":"CFTR protein repair therapy in cystic fibrosis","volume":"50","author":"Quintana-Gallego","year":"2014","journal-title":"Arch Bronconeumol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jcf.2018.11.014","article-title":"The increasing challenge of genetic counseling for cystic fibrosis","volume":"18","author":"Foil","year":"2019","journal-title":"J Cyst Fibros"},{"key":"B8","first-page":"20","article-title":"Hyperechogenita intestina jako marker cystick\u00e9 fibr\u00f3zy u plodu (hyperechogenic fetal bowel as a marker of fetal cystic fibrosis)","volume":"80","author":"Sukupov\u00e1","year":"2015","journal-title":"Ceska Gynekol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/ajmg.10431","article-title":"Predicting the risk of cystic fibrosis with abnormal ultrasound signs of fetal bowel: results of a French molecular collaborative study based on 641 prospective cases","volume":"110","author":"Muller","year":"2002","journal-title":"Am J Med Genet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jcf.2020.11.006","article-title":"Southern KW; European CF society neonatal screening working group (ECFS NSWG). updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome\/cystic fibrosis screen positive, inconclusive diagnosis (CRMS\/CFSPID)","volume":"20","author":"Barben","year":"2021","journal-title":"J Cyst Fibros"},{"key":"B11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/gim.2015.68","article-title":"Cystic fibrosis carrier screening effects on birth prevalence and newborn screening","volume":"18","author":"Castellani","year":"2016","journal-title":"Genet Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.31083\/j.ceog4905105","article-title":"Cystic fibrosis assessment in infertile couples: genetic analysis trough the next generation sequencing technique","volume":"49","author":"D\u2019Alcamo","year":"2022","journal-title":"Clin Exp Obstet Gynecol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1542\/peds.107.4.699","article-title":"Genetic counseling and neonatal screening for cystic fibrosis: an assessment of the communication process","volume":"107","author":"Ciske","year":"2001","journal-title":"Pediatrics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.prrv.2020.08.005","article-title":"Does newborn screening improve early lung function in cystic fibrosis?","volume":"42","author":"Davies","year":"2022","journal-title":"Paediatr Respir Rev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/S1569-1993(23)00555-6","article-title":"P180 evaluation of clinical features of children with cystic fibrosis and CFSPID in newborn screening programme with IRT\/IRT protocol","volume":"22","author":"Baykal","year":"2023","journal-title":"J Cyst Fibros"},{"key":"B16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41436-019-0641-8","article-title":"Prenatal genetic testing for cystic fibrosis: a systematic review of clinical effectiveness and an ethics review","volume":"22","author":"Kessels","year":"2020","journal-title":"Genet Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"eS25","DOI":"10.1016\/S0929-693X(20)30047-6","article-title":"Genetic diagnosis in practice: from cystic fibrosis to CFTR-related disorders","volume":"27","author":"Pagin","year":"2020","journal-title":"Arch Pediatr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: from molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat Rev Genet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.arcped.2005.09.029","article-title":"Les g\u00e8nes modificateurs dans la mucoviscidose (modifier genes and cystic fibrosis)","volume":"13","author":"Corvol","year":"2006","journal-title":"Arch Pediatr"},{"key":"B20","doi-asserted-by":"publisher","first-page":"582964","DOI":"10.3389\/fped.2020.582964","article-title":"Current approach in the diagnosis and management of allergic bronchopulmonary aspergillosis in children with cystic fibrosis","volume":"8","author":"Sunman","year":"2020","journal-title":"Front Pediatr"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1016\/j.jcf.2019.08.010","article-title":"Growth failure and treatment in cystic fibrosis","volume":"18","author":"Le","year":"2019","journal-title":"J Cyst Fibros"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/13543784.2020.1805733","article-title":"Cystic fibrosis\u2014ten promising therapeutic approaches in the current era of care","volume":"29","author":"Somayaji","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/ppul.20909","article-title":"Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis","volume":"43","author":"Dellon","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"465230","DOI":"10.1100\/2012\/465230","article-title":"Hypertonic saline in treatment of pulmonary disease in cystic fibrosis","volume":"2012","author":"Reeves","year":"2012","journal-title":"ScientificWorldJournal"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1824-7288-38-2","article-title":"Effects of chest physiotherapy and aerobic exercise training on physical fitness in young children with cystic fibrosis","volume":"38","author":"Elbasan","year":"2012","journal-title":"Ital J Pediatr"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3390\/children9081258","article-title":"Antibiotherapy in children with cystic fibrosis-an extensive review","volume":"9","author":"Ciuca","year":"2022","journal-title":"Children (Basel)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"127152","DOI":"10.1016\/j.micres.2022.127152","article-title":"Antimicrobial peptides for tackling cystic fibrosis related bacterial infections: a review","volume":"263","author":"Bugli","year":"2022","journal-title":"Microbiol. Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"16012","DOI":"10.1038\/npjbiofilms.2016.12","article-title":"Reaction-diffusion theory explains hypoxia and heterogeneous growth within microbial biofilms associated with chronic infections","volume":"2","author":"Stewart","year":"2016","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1128\/AAC.06486-11","article-title":"In vivo pharmacokinetics\/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection","volume":"56","author":"Hengzhuang","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"B30","doi-asserted-by":"publisher","first-page":"210055","DOI":"10.1183\/16000617.0055-2021","article-title":"The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects","volume":"30","author":"Van den Bossche","year":"2021","journal-title":"Eur Respir Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0064622","DOI":"10.1128\/aac.00646-22","article-title":"Effectiveness and safety of Beta-lactam antibiotics with and without therapeutic drug monitoring in patients with Pseudomonas aeruginosa pneumonia or bloodstream infection","volume":"66","author":"Kunz Coyne","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"B32","doi-asserted-by":"publisher","first-page":"105461","DOI":"10.1016\/j.micpath.2022.105461","article-title":"Prevalence of antibiotic resistance of Pseudomonas aeruginosa in cystic fibrosis infection: a systematic review and meta-analysis","volume":"165","author":"Bonyadi","year":"2022","journal-title":"Microb Pathog"},{"key":"B33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/antibiotics12020217","article-title":"Antibiotic resistance in patients with cystic fibrosis: past. present, and future","volume":"12","author":"Perikleous","year":"2023","journal-title":"Antibiotics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jpeds.2014.01.022","article-title":"Pancreatic enzyme replacement therapy dosing and nutritional outcomes in children with cystic fibrosis","volume":"164","author":"Haupt","year":"2014","journal-title":"J Pediatr"},{"key":"B35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3390\/genes11060589","article-title":"The changing epidemiology of cystic fibrosis: incidence. Survival and Impact of the CFTR Gene Discovery","volume":"11","author":"Scotet","year":"2020","journal-title":"Genes (Basel)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.prrv.2020.05.002","article-title":"CFTR modulator therapies\u2014effect on life expectancy in people with cystic fibrosis","volume":"42","author":"Balfour-Lynn","year":"2022","journal-title":"Paediatr Respir Rev"},{"key":"B37","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"2021","journal-title":"J Cyst Fibros"},{"key":"B38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","article-title":"Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function","volume":"13","author":"Van Goor","year":"2014","journal-title":"J Cyst Fibros"},{"key":"B39","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1378\/chest.11-2672","article-title":"Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation","volume":"142","author":"Flume","year":"2012","journal-title":"Chest"},{"key":"B40","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jcf.2011.12.005","article-title":"Ivacaftor potentiation of multiple CFTR channels with gating mutations","volume":"11","author":"Yu","year":"2012","journal-title":"J Cyst Fibros"},{"key":"B41","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1183\/09059180.00008512","article-title":"Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation","volume":"22","author":"Sermet-Gaudelus","year":"2013","journal-title":"Eur Respir Rev"},{"key":"B42","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2020","journal-title":"Front Pharmacol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"190112","DOI":"10.1183\/16000617.0112-2019","article-title":"Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease","volume":"29","author":"Shteinberg","year":"2020","journal-title":"Eur Respir Rev"},{"key":"B45","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jcf.2020.07.015","article-title":"Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants","volume":"20","author":"Laselva","year":"2021","journal-title":"J Cyst Fibros"},{"key":"B46","doi-asserted-by":"publisher","first-page":"200016","DOI":"10.1183\/20734735.0016-2020","article-title":"The era of CFTR modulators: improvements made and remaining challenges","volume":"16","author":"Cuevas-Oca\u00f1a","year":"2020","journal-title":"Breathe (Sheff)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e16144","DOI":"10.7759\/cureus.16144","article-title":"A review of trikafta: triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy","volume":"13","author":"Zaher","year":"2021","journal-title":"Cureus"},{"key":"B48","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.cell.2019.12.032","article-title":"A therapy for most with cystic fibrosis","volume":"180","author":"Bear","year":"2020","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/17476348.2023.2179989","article-title":"Managing cystic fibrosis in children aged 6\u201311yrs: a critical review of elexacaftor\/tezacaftor\/ivacaftor combination therapy","volume":"17","author":"Jordan","year":"2023","journal-title":"Expert Rev Respir Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in infants aged 4 to <12 months with cystic fibrosis and a gating mutation. Results of a two-part phase 3 clinical trial","volume":"203","author":"Davies","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jcf.2018.10.015","article-title":"Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis","volume":"18","author":"Sermet-Gaudelus","year":"2019","journal-title":"J Cyst Fibros"},{"key":"B52","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1089\/jamp.2018.1502","article-title":"The cystic fibrosis-like airway surface layer is not a significant barrier for delivery of eluforsen to airway epithelial cells","volume":"32","author":"Brinks","year":"2019","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"B53","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejmech.2015.06.038","article-title":"Enhancement of premature stop codon readthrough in the CFTR gene by ataluren (PTC124) derivatives","volume":"101","author":"Pibiri","year":"2015","journal-title":"Eur J Med Chem"},{"key":"B54","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1183\/09031936.00120910","article-title":"Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis","volume":"38","author":"Wilschanski","year":"2011","journal-title":"Eur Respir J"},{"key":"B55","doi-asserted-by":"publisher","first-page":"10558","DOI":"10.1093\/nar\/gkab7882","article-title":"Functional correction of CFTR mutations in human airway epithelial cells using adenine base editors","volume":"49","author":"Krishnamurthy","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1016\/j.jcf.2019.12.012","article-title":"New approaches to genetic therapies for cystic fibrosis","volume":"19","author":"Christopher Boyd","year":"2020","journal-title":"J Cyst Fibros"},{"key":"B57","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1378\/chest.07-1631","article-title":"Airway inflammation in cystic fibrosis","volume":"133","author":"Elizur","year":"2008","journal-title":"Chest"},{"key":"B58","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jcf.2004.06.006","article-title":"Cytokines and inflammatory mediators in cystic fibrosis","volume":"3","author":"Courtney","year":"2004","journal-title":"J Cyst Fibros"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/thoraxjnl-2013-203204","article-title":"Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications","volume":"68","author":"Cohen-Cymberknoh","year":"2013","journal-title":"Thorax"},{"key":"B60","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.smim.2017.08.007","article-title":"Recent advances in clinical development of leukotriene B4 pathway drugs","volume":"33","author":"Bhatt","year":"2017","journal-title":"Semin Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/978-3-030-50621-6_4","article-title":"Targeting leukotrienes as a therapeutic strategy to prevent comorbidities associated with metabolic stress","volume":"1274","author":"Ramalho","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"102206","DOI":"10.1016\/j.coph.2022.102206","article-title":"TMEM16A (ANO1) as a therapeutic target in cystic fibrosis","volume":"64","author":"Galietta","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"102248","DOI":"10.1016\/j.coph.2022.102248)","article-title":"Mucus-targeting therapies of defective mucus clearance for cystic fibrosis: a short review","volume":"65","author":"Figueira","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jcf.2020.07.023","article-title":"A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation","volume":"20","author":"Davies","year":"2021","journal-title":"J Cyst Fibros"},{"key":"B65","first-page":"306","article-title":"Effect of 8 weeks of lumacaftor in combination with ivacaftor in patients with CF and heterozygous for the F508del CFTR mutation","volume":"49","author":"Rowe","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"B67","first-page":"287","article-title":"Effect of lumacaftor in combination with ivacaftor on FEV1 and safety measures in patients aged 6\u201311 years with CF who are homozygous for F508del-CFTR","volume":"49","author":"Rosenfeld","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"B68","volume-title":"Two 24-week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who Have Two Copies of the F508del Mutation","year":"2014"},{"key":"B69","doi-asserted-by":"publisher","first-page":"246ra97","DOI":"10.1126\/scitranslmed.3008889","article-title":"Some gating potentiators, including VX-770, diminish \u0394F508-CFTR functional expression","volume":"6","author":"Veit","year":"2014","journal-title":"Sci Transl Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"246ra96","DOI":"10.1126\/scitranslmed.3008680","article-title":"Potentiator ivacaftor abrogates pharmacological correction of \u0394F508 CFTR in cystic fibrosis","volume":"6","author":"Cholon","year":"2014","journal-title":"Sci Transl Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"5613","DOI":"10.1021\/bi501007v","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) potentiators protect G551D but not \u0394F508 CFTR from thermal instability","volume":"53","author":"Liu","year":"2014","journal-title":"Biochemistry"},{"key":"B72","first-page":"S157","article-title":"Phase 2 studies reveal additive effects of VX-661, and investigational CFTR corrector, and ivacaftor, a CFTR potentiator, in patients with CF who carry the F508del-CFTR mutation","volume":"49","author":"Pilewski","year":"2014","journal-title":"Pediatric Pulmonol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nchembio.275","article-title":"Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis","volume":"6","author":"Hutt","year":"2010","journal-title":"Nat Chem Biol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.cell.2008.06.037","article-title":"Chemical and biological approaches synergize to ameliorate protein-folding diseases","volume":"134","author":"Mu","year":"2008","journal-title":"Cell"},{"key":"B75","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1042\/BJ20071420","article-title":"Enhanced cell-surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones","volume":"410","author":"Varga","year":"2008","journal-title":"Biochem J"},{"key":"B76","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1042\/BJ20090389","article-title":"Dynasore inhibits removal of wild-type and DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) from the plasma membrane","volume":"421","author":"Young","year":"2009","journal-title":"Biochem J"},{"key":"B77","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","article-title":"Future therapies for cystic fibrosis","volume":"14","author":"Allen","year":"2023","journal-title":"Nat Commun"},{"key":"B78","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jcf.2021.06.003","article-title":"Antisense oligonucleotide-based drug development for cystic fibrosis patients carrying the 3849+10kb C-to-T splicing mutation","volume":"20","author":"Oren","year":"2021","journal-title":"J Cyst Fibros"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1393193\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:03:03Z","timestamp":1715317383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1393193\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":78,"alternative-id":["10.3389\/fped.2024.1393193"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1393193","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"article-number":"1393193"}}